{
  "id": 9151196,
  "title": "An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide",
  "url": "https://urgent.news/2026/09/22/an-orexin-drugs-proof-of-concept-in-adhd-cues-unwarranted-share-slide",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-22T14:17:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/orexin-adhd-cue-urticaria-/830847/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}